Light Therapy for Onychomycosis Study

  • End date
    Jun 19, 2023
  • participants needed
  • sponsor
    ToeFX Inc.
Updated on 21 March 2022
Accepts healthy volunteers


This is a pilot prospective study designed to capture information about the safety and effectiveness of the ToeFX Therapy Light.


According to a report published by the NCBI on January 14, 2015, some 3 to 12% of the population is affected by toenfail fungus, with older populations more likely to be affected. Indeed, fungal infection of nails (onychomycosis) is among the most prevalent infectious diseases in humans. According to a communication released by the Ontario College of Physicians and Surgeons in September 2019, the cure rate for topical treatments is only 6-23% after 1 year. Even after 1 year of treatment, topical treatments have limited efficacy. Moreover, onychomycosis is cosmetically distressing.

This study will be an open-label, prospective pilot study. The subjects will be 100 patients who suffer from distal subungual onychomycosis. The purpose of the study is to establish the efficacy of the ToeFX Therapy Light, which has shown compelling results in in vitro and ex vivo (cadaver) studies but has not been tested in patients. Specifically, the investigators wish to:

  1. Determine the safety and efficacy of this therapy in the treatment of distal subungual onychomycosis of the toenail.
  2. Determine the number of treatments required to clear the nail and to cure the fungus.
  3. Finalize the treatment protocol, device design and user interface.
  4. Test re-infection or recurrence of fungus post-treatment.

Condition Onychomycosis of Toenail
Treatment Single wavelength light (red) only, Dual wavelength light (red/blue)
Clinical Study IdentifierNCT05139888
SponsorToeFX Inc.
Last Modified on21 March 2022


Yes No Not Sure

Inclusion Criteria

have a clinical diagnosis of mild to moderate DSO in the nail of at least one great toe, with 20% to 50% clinical involvement of the target toenail, without dermatophytomas or lunula (matrix) involvement, without lunular or proximal involvement
exhibit positive mycology results (i.e., KOH test and culture of a dermatophyte) from the target great toenail, confirming common dermatophytes such as T. rubrum
are willing to refrain from using polish or other medication on treated toenails or on the skin immediately adjacent to the toenails during the treatment period unless directed to do so by the investigator
are willing to refrain from using topical steroids or topical antifungals on toenails or the skin immediately adjacent to the toenails or systemic antifungals for the duration of the study
are willing to provide signed and dated written voluntary informed consent in English before any protocol-specific procedures are performed
are able to complete the study and comply with study instructions

Exclusion Criteria

females who are pregnant, plan to become pregnant during the study, or are nursing a child
persons who are hypersensitive to topical creams, ointments, medications, or surfactants
persons who have received systemic antifungal therapy for any reason within 3 months, or topical antifungal therapy on the toenails or skin immediately adjacent to the toenails within 3 weeks prior to the start of the study
persons who have received an investigational drug within 4 weeks of the first dose of study product, or who are scheduled to receive an investigational drug other than the study product during the study
persons who have participated in a clinical trial for the systemic treatment of onychomycosis of the toenails within 6 months prior to the first dose of study product
persons who are not prepared to give up use of any nail cosmetic products for the duration of the study
persons who have any known immunodeficiency or history of malignancy in the last 4 years, excluding nonmelanoma skin cancer
persons currently suffering from any disease or condition, that could include abnormal laboratory tests, and/or who are currently using medication which in the opinion of the investigator may affect the evaluation of the study product or place the subject at undue risk
persons with psoriasis, lichen planus, or other medical conditions known to induce nail changes, other abnormalities or can causes of nail breakdown that can predispose to secondary fungal infection. Trauma from ill-fitting shoes, running, or overly aggressive nail care can also induce changes visually indistinguishable from onychomycosis that could result in a clinically abnormal toenail
patients with glucose-6 phosphate dehydrogenase (G6PD) deficiency or hypersensitivity/allergies to methylene blue
persons with a history of any condition that could possibly affect absorption of drug (e.g., gastrectomy), uncontrolled diabetes, clinically significant peripheral vascular disease or peripheral circulatory impairment, or has had any major illness within 30 days prior to the screening examination
persons with a history of drug, prescription medicine, or alcohol abuse within the past 2 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note